{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"25","upperLimit":"71","value":"42"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"OS12 is defined as the percentage of participants still alive at 12 months, and is the clinical efficacy, primary endpoint for Stratum A. Any eligible participant that received at least one dose of the K27M/TT vaccine will be considered evaluable for clinical efficacy. OS12 will be censored at the last contact date and estimated using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Newly diagnosed children with diffuse intrinsic pontine glioma who are positive for HLA-A2 and the H3.3K27M mutation that underwent radiation therapy will receive the specific H3.3K27M peptide vaccine, combined with the tetanus toxoid (TT) peptide, emulsified in Montanide. Poly-ICLC, which is a synthetic nucleic acid, will be given concurrently to improve the therapeutic effects of the vaccine. Vaccine will be given every 3 weeks for the first 24 weeks, then if there is stable or improved disease, will be given every 6 weeks for a total treatment period of 96 weeks.","id":"OG000","title":"Stratum A: Newly Diagnosed DIPG"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"12 months","title":"Overall Survival Rate at 12 Months (OS12) (Stratum A Only)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}